Archives

Development of a Probody Drug Conjugate (PDC) Targeting CD71 for the Treatment of Cancer

Presented at 10th Annual World Antibody Drug Conjugate Conference. London, United Kingdom March 4, 2020
Luc Desnoyers, Ph.D.

Learn More

CD166-DM4 Probody™ Drug Conjugate (CX-2009) Treatment of 198 Patient -derived Xenograft Models (PDX) in a Mouse Clinical Trial Format

Bob Y. Liu, Joel Shen, Matthias Will, Sreeni Yalamanchili, Judi Ford-Gordon, Mark Stroh, Jennifer Richardson, Annie Yang-Weaver, Luc R. Desnoyers, Marcia Belvin, W. Michael Kavanaugh, Siew Schleyer. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia.

Learn More

PROCLAIM-CX-072: Monotherapy for Advanced Triple-Negative Breast Cancer With Skin Metastases in a Phase 1/2a Trial of the PD-L1 Probody Therapeutic CX-072

Sylvia Adams, Erika Hamilton, Patrick A. Ott, Daniel Cho, Kevin Kalinsky, Patricia LoRusso, Matthias Will, Vanessa Huels, Beverly Benson, Carmen Murias, Hendrik-Tobias Arkenau. Poster presented at the 41st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas.

Learn More

Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a Phase 1/2 Trial

Susan K. Lyman, Judi Gordon, Amy DuPage, Preeti Pramanik, Bruce Howng, Ivan A. Zein, Michael B. Winter, Irina K. Popova, Olga Vasiljeva, James Jones, Ken Wong, Victoria Singson, Jennifer Richardson, Beiyao Zheng, Mark Stroh, Lori Carman, Vanessa Huels, Karen Autio, Valentina Boni, Daniel Cho, Javier Garcia-Corbacho, Iván Victoria Ruiz, Omid Hamid, Nataliya Uboha, Elisabeth de Vries, Anthony El-Khoueiry, Alexander Spira, Rachel E. Sanborn, Fiona Thistlethwaite, Hendrik-Tobias Arkenau, Johanna Bendell, Patrick A. Ott, Naiyer Rizvi, Matthias Will, W. Michael Kavanaugh, Aung Naing, Luc R. Desnoyers. Poster presented at SITC 2018, November 7-11, Washington, D.C.

Learn More

Preliminary Results of PROCLAIM-CX-072: The First-in-Human, Dose-Finding Trial of PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients With Advanced Solid Tumors

Valentina Boni, Javier Garcia-Corbacho, Patrick A. Ott, Daniel Cho, Karen A. Autio, Nataliya Uboha, Alexander I. Spira, Rachel Humphrey, Matthias Will, Aung Naing, Fiona Thistlethwaite, Elisabeth de Vries, Hendrik-Tobias Arkenau. Poster presented at ESMO 2018, October 19-23, Munich, Germany.

Learn More

Preliminary Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial Evaluating the PD-L1 Probody Therapeutic CX-072 in Combination With Ipilimumab in Patients With Advanced Solid Tumors

Ruth Plummer, Rachel E. Sanborn, Elisabeth de Vries, Patricia LoRusso,Hendrik-Tobias Arkenau, Nataliya Uboha, Jerzy Wydmanski, Mary Josephine Fidler, Valentina Boni, Javier Garcia-Corbacho, Rachel Humphrey, Matthias Will, Karen A. Autio, Anthony El-Khoueiry, C. Willemien Menke-van der Houven van Oordt, Fiona Thistlethwaite. Poster presented at ESMO 2018, October 19-23, Munich, Germany.

Learn More

Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates

Lin J., Sagert J. (2018) Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates. In: Damelin M. (ed). Innovations for Next-Generation Antibody-Drug Conjugates. Cancer Drug Discovery and Development. Humana Press, Cham.

Learn More

Preliminary Interim Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic (Pb-Tx) CX-072 in Combination with Ipilimumab (ipi) in Patients (pts) with Advanced Solid Tumors

Rachel E. Sanborn, Catharina Wilhelmina Menke, Karen A. Autio, Hendrik-Tobias Arkenau, Javier Garcia Corbacho, Patricia LoRusso, Elizabeth Ruth Plummer, Nataliya Volodymyrivna Uboha, Morganna Louise Freeman, Jerzy Wydmanski, Vanessa Huels, Beiyao Zheng, Matthias Will, Rachel W. Humphrey, Fiona Thistlethwaite, Elisabeth G.E. de Vries, Anthony B. El-Khoueiry. Poster presented at ASCO 2018, June 1-5, Chicago, Illinois.

Learn More

Preliminary Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients (pts) with Advanced Solid Tumors

Karen A. Autio, Hendrik-Tobias Arkenau, Bert H. O’Neil, Johanna C. Bendell, Anthony El-Khoueiry, James Strauss, Amy Weise, Nataliya Volodymyrivna Uboha, Naiyer A. Rizvi, Beiyao Zheng, Luc Desnoyers, Mark Stroh, Lori Carman, Rachel W. Humphrey, Matthias Will, Valentina Boni, Alexander I. Spira, Aung Naing. Poster presented at ASCO 2018, June 1-5, Chicago, Illinois.

Learn More

Development of a Probody™ Drug Conjugate (PDC) Targeting CD166 for the Treatment of Multiple Cancers

Annie Yang Weaver, Shweta Singh, Amy DuPage, Jason Sagert, Jeanne Flandez, Elizabeth Menendez, Judi Ford, Michael Krimm, Stephen Moore, Margaret Nguyen, Andrew Jang, Eric Brecht, Yuanhui Huang, Linnea Diep, Nicole Lapuyade, Tereza Sputova, James West, Olga Vasiljeva, Shouchun Liu, Jennifer Richardson, W. Michael Kavanaugh, Jonathan A. Terrett, Luc R. Desnoyers. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015, November 5-9, Boston, Massachusetts.

Learn More